Copyright © Inderes 2011 - present. All rights reserved.

AlzeCure Pharma

2.43 SEK

+1.25 %

Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+1.25 %
+22.42 %
-31.16 %
-25.44 %
+122.39 %
+110.49 %
-39.47 %
-71.19 %
-74.34 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Read more
Market cap
279.24M SEK
Turnover
75.5K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

5/5
2026

Interim report Q1'26

14/5
2026

General meeting '26

ShowingAll content types
Third party research

AlzeCure Pharma: Breddar ACD856-program - Analysguiden

Alzecure drar i gång en avslutande fas 1-studie med ACD-856 för att dokumentera högre doser jämfört med doseringen i den senaste studien. Denna breddning av programmet kan öppna för behandling av bland annat svår depression. Vi ser den nya studien som...

AlzeCure Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

AlzeCure Pharma: Nytt ljus på ACD440 - Analysguiden

Alzecures nyemission bereder vägen för en europeisk fas 2a-studie med ACD856 på patienter med tidig Alzheimer. Samtidigt samlar bolaget argument för att nå en licensaffär med ACD440. En nyligen publicerad artikel pekar på smärtlindrande effekt i en undergrupp...

AlzeCure Pharma
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.